Inflammation Research

, Volume 67, Issue 7, pp 617–626 | Cite as

Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH)

  • Irene Paterniti
  • Michela Campolo
  • Marika Cordaro
  • Rosalba Siracusa
  • Antonio Filippone
  • Emanuela Esposito
  • Salvatore Cuzzocrea
Original Research Paper


Objective and design

To characterize the impact of inflammatory process and oxidative stress in the degree of benign prostatic hyperplasia (BPH), a common condition in which chronic inflammation plays a crucial role, we investigated the effect of different plant extract preparations in an in vivo model of BPH as new therapeutic target.


BPH was made in rats with daily administration of testosterone propionate (3 mg/kg) for 14 days.


Rats were randomized into different groups to receive oral administration of plant extract preparations: Serenoa repens with selenium (SeR 28.5 mg/kg associated with Se 0.005 mg/kg), Teoside (2 mg/kg), and Puryprost (14 mg/kg containing Teoside 50% 2 mg/kg and Epilobium 12 mg/kg).


After 14 days, rats were killed and histological changes, prostate weight and apoptotic pathways were assayed.


The results obtained demonstrated that the association of treatments reduced prostate weight and hyperplasia, while treatment with Puryprost demonstrated a greater trend of protection compared to the other treatments.


Thus, our results indicate that plant extract could be considered as new useful therapy in the treatment of BPH with particular attention on Puryprost that represents a rational approach to reduce BPH through modulation of inflammatory process and anti-oxidant process.


Benign prostatic hyperplasia Inflammation Oxidative stress Natural extract 



The authors would like to thank Maria Antonietta Medici for her excellent technical assistance during this study and Mr. Francesco Soraci for his secretarial and administrative assistance and Miss. Valentina Malvagni for her editorial assistance with the manuscript.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.


  1. 1.
    Kessler OJ, Keisari Y, Servadio C, Abramovici A. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol. 1998;159(3):1049–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004;172(5 Pt 1):1784–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202–16. Scholar
  4. 4.
    Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2008;108(3–5):254–60. Scholar
  5. 5.
    Comhaire F, Mahmoud A. Preventing diseases of the prostate in the elderly using hormones and nutriceuticals. Aging Male. 2004;7(2):155–69.CrossRefPubMedGoogle Scholar
  6. 6.
    Suzuki M, Ito Y, Fujino T, Abe M, Umegaki K, Onoue S, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009;30(3):227–81. Scholar
  7. 7.
    Minutoli L, Altavilla D, Marini H, Rinaldi M, Irrera N, Pizzino G, et al. Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of Serenoa repens, selenium and lycopene. J Biomed Sci. 2014;21:19. Scholar
  8. 8.
    Pagano E, Laudato M, Griffo M, Capasso R. Phytotherapy of benign prostatic hyperplasia. A minireview. Phytother Res. 2014;28(7):949–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Granica S, Piwowarski JP, Czerwinska ME, Kiss AK. Phytochemistry, pharmacology and traditional uses of different Epilobium species (Onagraceae): a review. J Ethnopharmacol. 2014;156:316 – 46. Scholar
  10. 10.
    Allkanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci. 2015;126:42–56. Scholar
  11. 11.
    Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C, et al. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br J Pharmacol. 2012;167(1):95–108. Scholar
  12. 12.
    Paterniti I, Impellizzeri D, Di Paola R, Esposito E, Gladman S, Yip P, et al. Docosahexaenoic acid attenuates the early inflammatory response following spinal cord injury in mice: in-vivo and in-vitro studies. J Neuroinflammation. 2014;11:6. Scholar
  13. 13.
    Cordaro M, Paterniti I, Siracusa R, Impellizzeri D, Esposito E, Cuzzocrea S. KU0063794, a dual mTORC1 and mTORC2 inhibitor, reduces neural tissue damage and locomotor impairment after spinal cord injury in mice. Mol Neurobiol. 2016. Scholar
  14. 14.
    Paterniti I, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Galuppo M, et al. Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma. J Neurochem. 2010;112(3):611–24. Scholar
  15. 15.
    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics 2004 CA: a cancer journal for clinicians. 2004;54(1):8–29.Google Scholar
  16. 16.
    Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol. 2012;188(2):496–501. Scholar
  17. 17.
    Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005;173(4):1309–13. Scholar
  18. 18.
    Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178(2):395–401. Scholar
  19. 19.
    Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91(7):2562–8. Scholar
  20. 20.
    Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, et al. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate. 2014;74(6):669–79. Scholar
  21. 21.
    Pace G, Di Massimo C, De Amicis D, Corbacelli C, Di Renzo L, Vicentini C, et al. Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int. 2010;85(3):328–33. Scholar
  22. 22.
    Naber KG, Weidner W. Chronic prostatitis-an infectious disease? J Antimicrob Chemother. 2000;46(2):157–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2005;26(7):1170–81. Scholar
  24. 24.
    Larre S, Camparo P, Comperat E, Boulbes D, Haddoum M, Baulande S, et al. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl. 2012;14(3):499–504. Scholar
  25. 25.
    Khan N, Adhami VM, Mukhtar H. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer. 2009;61(6):836–41. Scholar
  26. 26.
    Cordaro M, Impellizzeri D, Siracusa R, Gugliandolo E, Fusco R, Inferrera A, et al. Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. Toxicol Appl Pharmacol. 2017;329:231–40. Scholar
  27. 27.
    Larre S, Tran N, Fan C, Hamadeh H, Champigneulles J, Azzouzi R, et al. PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat. 2008;87(1–4):14–9. Scholar
  28. 28.
    Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Koutsilieris M. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res. 2005;25(4):3123–33.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Irene Paterniti
    • 1
  • Michela Campolo
    • 1
  • Marika Cordaro
    • 1
  • Rosalba Siracusa
    • 1
  • Antonio Filippone
    • 2
  • Emanuela Esposito
    • 1
  • Salvatore Cuzzocrea
    • 1
    • 3
  1. 1.Department of Chemical, Biological, Pharmaceutical and Environmental SciencesUniversity of MessinaMessinaItaly
  2. 2.Department of Biomedical and Biotechnological ScienceUniversity of CataniaCataniaItaly
  3. 3.Department of Pharmacological and Physiological ScienceSaint Louis UniversitySt. LouisUSA

Personalised recommendations